Autoinflammatory & rare systemic diseases
Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease
Authors' conclusion
CCL19 is a novel and promising biomarker for the longitudinal monitoring of disease activity in patients with IgG4-RD and may provide supplemental value to IgG4 in identifying relapsing disease.
Study context
- Population
- Patients with igG4-related disease (IgG4-RD), healthy donors and patients with sarcoidosis
- Comparison
- IgG4-RD vs healthy donors and sarcoidosis
- Outcome
- Biomarkers distinguishing active IgG4-RD from remission
Methodological detailsbroad screening of 92 inflammation-associated proteins, adjusted for age, sex, race and false discovery rate, enzyme-linked immunosorbent assay (ELISA) validation cohort with age, sex and race-matched healthy donors (HDs), paired longitudinal samples
- Broad screening of 92 inflammation-associated proteins
- Adjusted for age, sex, race and false discovery rate
- ELISA validation cohort with age, sex and race-matched HDs
- Paired longitudinal samples
Performance
As reported in the abstract
- Inflammation-associated proteins distinguishing IgG4-RD
- 12
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease. Ann Rheum Dis. Published 13 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →